Abstract:BackgroundAn ageing population and lifestyle changes have led to increased cardiovascular disease-related morbidity and mortality in China, where an estimated 230 million people have cardiovascular disease. Long-term antiplatelet therapy with aspirin and clopidogrel are used for treatment and post-stenting primary prevention of acute coronary syndrome, but the risk of bleeding complications is high. This study aimed to identify the target of the newly developed antiplatelet agent ADTM, originating from traditional Chinese herbs. We also investigated the antiplatelet and cardioprotective effects of ADTM.MethodsWe developed ADTM by conjugating danshensu and tetramethylpyrazine, which are active compounds in the herbs danshen (Salvia miltiorrhizae) and chuanxiong (Ligustium wallichii Franch), respectively. To identify the target of ADTM, we incubated its biotinylated analogue with rat blood platelet lysates, then used chemical proteomics to precipitate protein complexes. We compared the antiplatelet effect of ADTM with clopidogrel in a rat model in vivo by administrating ADTM (5–20 mg/kg) and clopidogrel (18 mg/kg) intravenously daily for 5 days, and inducing platelet aggregation by adenosine diphosphate. We also assessed the inhibitory effects of ADTM and clopidogrel on ferric chloride (FeCl3)-induced venous thrombus formation. We further assessed the cardioprotective effects of ADTM in a canine coronary artery occlusion-reperfusion model. The left anterior descending coronary artery was occluded for 20 min followed by reperfusion in five beagles (weighing about 12 kg). 15 min after occlusion, ADTM (6mg/kg) or nitroglycerin (45 μg) was administered for 3 min continuously.FindingsResults of chemical proteomics showed that ADTM targets ERp57. The inhibitory effects of ADTM on platelet aggregation were similar to clopidogrel in the rat model (mean 40% [SD 11] for ADTM [p=0·018 vs control] and 38% [9] for clopidogrel [p=0·0073 vs control; p=0·78 vs ADTM). Similarly, the inhibitory effects on FeCl3-induced venous thrombus formation were 50% (SD 10) for ADTM (p=0·0087 vs vehicle control) and 42% (6) for clopidogrel (p=0·0093 vs vehicle control; p=0·85 vs ADTM). ADTM increased mean coronary blood flow by 36% (SD 15; p=0·0165 for before vs after ADTM administration) and decreased mean arterial pressure (MAP) from 102 mm Hg (2·7) to 96 mm Hg (1·3; p=0·0031). Coronary blood flow did not differ between before and after nitroglycerin administration (p=0·49), but nitroglycerin did decrease mean arterial pressure from 102 mm Hg (1·6) to 92 mm Hg (1·5; p=0·0076). ADTM and nitroglycerin reduced the infarct size of cardiac tissue by a mean of 10% (SD 3; p=0·0217) and 8% (2; p=0·0072), respectively.InterpretationADTM is a ligand that targets ERp57 and displays antiplatelet and cardioprotective effects in animal models. ADTM represents a potential lead compound for further investigation and development of new antiplatelet drugs with reduced bleeding risk.FundingThe National Natural Science Foundation of China (NSFC-81403139) and University of Macau (MYRG2015-00161-ICMS-QRCM).

Potential Target-Related Proteins in Rabbit Platelets Treated with Active Monomers Dehydrocorydaline and Canadine from Rhizoma Corydalis

Differential Proteomic Analysis of Platelets Suggested Target-Related Proteins in Rabbit Platelets Treated with Rhizoma Corydalis

Simultaneous Screening and Analysis of Antiplatelet Aggregation Active Alkaloids from Rhizoma Corydalis

Effect of total alkaloids from Rhizoma Corydalis Decumbeutis on blood viscosity and platelet aggregation in rabbits

Effect on Platelet Aggregation Activity: Extracts from 31 Traditional Chinese Medicines with the Property of Activating Blood and Resolving Stasis

Structure-Antiplatelet Activity Relationships of Novel Ruthenium (II) Complexes: Investigation of Its Molecular Targets

Atractylodes Lactone Compounds Inhibit Platelet Activation

Components of Traditional Chinese Medicine Inhibit Platelet Aggregation by Blocking ADP Receptor Subtypes P2Y1 and P2Y12

2,3,5,4’-Tetrahydroxystilbene-2-o-β-d-glucoside (THSG) Attenuates Human Platelet Aggregation, Secretion and Spreading in Vitro

Thrombosis inhibited by Corydalis decumbens through regulating PI3K-Akt pathway

Inhibitory Effect of TBN on Platelet Aggregation in Rabbit

[Influences of 3,4,5-Trihydroxystibene-3-beta-mono-d-glucoside on Rabbits' Platelet Aggregation and Thromboxane B2 Production in Vitro].

Influence of Hexapeptide on Rabbit Platelet Aggregation Activity

MC-002 exhibits positive effects against platelets aggregation and endothelial dysfunction through thromboxane A2 inhibition.

Comparative Study on Effects of Active Ingredients of Several Traditional Chinese Medicines on Rabbit Platelet Aggregation in Vitro

Combination of Platelet Bio-Specific Extraction and High-Performance Liquid Chromatography with Diode-Array Detection/liquid Chromatography-Mass Spectrometry Method for Analyzing Platelet-Targeted Compounds in Rhizoma Chuanxiong

Abstract 3094: Traditional Chinese Medicine Buyang Huanwu Decoction Regulates The Platelet Gpvi And Its Downstream Protein Signaling Pathways,inhibiting Thrombosis And Preventing Cardiovascular Disease.

Effective components and mechanism analysis of anti-platelet aggregation effect of Justicia procumbens L.

Development of the Novel Antiplatelet Agent ADTM, Originating from Traditional Chinese Medicine: a Chemical Proteomic Analysis and In-Vivo Assessment of Efficacy in an Animal Model

Selective Inhibition of P2Y1 and P2Y12 Receptor Signal Pathways in Platelet Aggregation in Transgenic Cell Lines and Rats by Potassium 2-(1-hydroxypentyl)-benzoate, Puerarin and Salvianolic Acid B.

Plasma Pharmacological Study on Da Huang Zhe Chong Capsule on Platelet Aggregation of Normal Person